Delvert, Rosalie http://orcid.org/0000-0002-1524-8071
Charles, Marie-Aline http://orcid.org/0000-0003-4025-4390
Leynaert, Bénédicte http://orcid.org/0000-0001-5045-2492
Kadawathagedara, Manik http://orcid.org/0009-0002-3363-6219
Adel-Patient, Karine http://orcid.org/0000-0002-2242-0626
Divaret-Chauveau, Amandine http://orcid.org/0000-0002-2492-9864
Dufourg, Marie-Noëlle http://orcid.org/0000-0002-4209-934X
Raherison, Chantal http://orcid.org/0000-0003-0015-2883
Varraso, Raphaëlle http://orcid.org/0000-0002-3338-7825
de Lauzon-Guillain, Blandine http://orcid.org/0000-0001-5887-8842
Bédard, Annabelle http://orcid.org/0000-0002-7842-8889
Funding for this research was provided by:
Agence Nationale de la Recherche (ANR-19-CE36-0008)
Article History
Received: 17 March 2024
Accepted: 29 May 2024
First Online: 6 June 2024
Competing interests
: R. Delvert declares no competing interests. M.A. Charles declares no competing interests. B. Leynaert declares no competing interests. M. Kadawathagedara declares no competing interests. K. Adel-Patient declares no competing interests. A. Divaret-Chauveau, outside of the submitted work, reports grants from the French public agency ANSES, Don du Souffle, Novartis, ARAIRLOR, consulting fees for Sanofi, Stallergens, ALK, Aimmune Therapeutics, payment for presentations for Aimmune Therapeutics, Novartis, ALK, support for attending meetings from Mead Johnson, Nutricia, Aimmune Therapeutics, Novartis, ALK, stocks from Essilor Luxottica. M.N. Dufourg declares no competing interests. C. Raherison, outside of the submitted work, reports contracts from Sanofi, payment for presentations from Novartis, AstraZeneka, GSK, support for attending meetings from Sanofi, AstraZeneca, Sanofi, participation on Advisory Board of Sanofi. R. Varraso declares no competing interests. B. de Lauzon-Guillain declares no competing interests. A. Bédard declares no competing interests.